Keywords
beta blockers
anxiety disorders
posttraumatic stress disorder
Abstract
Introduction. Beta blockers are mainly used in treating cardiovascular diseases. However, it has been observed that these drugs have also an anxiolytic potential. Over the years, a number of clinical trials have been conducted aimed at determining the effectiveness of beta blockers in treating anxiety disorders.
The aim. The main objective of the article is to present the significance and position of adrenolytic drugs in the pharmacotherapy of anxiety disorders on the basis of available literature. Moreover, the authors also decided to take into account the data from current research results, considering the problem of side effects of using adrenolytic drugs - especially the controversial reports on their effect on the development of affective disorders.
Method. An analysis was conducted of articles from Medline/PubMed database, selected on the basis of the following key words: anxiety disorders, beta blockers, adrenolytic drugs, as well as on the basis of their dates of publication: 1960-2017. In order to conduct a reliable and complete review of literature, the authors decided to include works from quite an extended period of time. The articles included in the review were published in Polish and English.
Results. The review of articles concerning the treatment of anxiety disorders clearly suggests that propranolol is effective in reducing the frequency of panic attacks and the tendency for avoidance behavior in patients with agoraphobia. Other studies report on potential benefits in terms of early interventional prevention and treating posttraumatic stress disorder with propranolol. However, there is lack of randomized clinical trials concerning the therapeutic effect of other adrenolytic drugs in treating anxiety disorders. Early research works reported that (mainly lipophilic) beta blockers may have a depressogenic effect; however, the latest studies have not confirmed it.
Conclusions. The contemporary research on the therapeutic potential of beta blockers in treating anxiety disorders is insufficient. What seems to be most promising, however, are reports concerning the desirable effects of using adrenolytic drugs in treating posttraumatic stress disorder, which implicates the necessity of conducting further research verifying the validity of their application.
References
1. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; American Psychiatric Publishing: Arlington, VA, USA, 2013.
2. Moller HJ, Bandelow B, Bauer M, et al. DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences-part 1: general aspects and paradigmatic discussion of depressive disorders. Eur Arch Psychiatry Clin Neurosci. 2015;265:5-18.
3. Bandelow B. Comparison of the DSM-5 and ICD-10: panic and other anxiety disorders. CNS Spectr. 2017:1-3.
4. Baldwin DS, Gordon R, Abelli M, Pini S. The separation of adult separation anxiety disorder. CNS Spectr. 2016;21:289-294.
5. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, American Psychiatric Association, 1994.
6. Stein DJ, Scott KM, de Jonge P, Kessler RC. Epidemiology of anxiety disorders: from surveys to nosology and back. Dialogues in clinical neuroscience, 2017;19:127.
7. Baxter AJ, Vos T, Scott KM, Norman RE, Flaxman AD, Blore J et al.. The regional distribution of anxiety disorders: implications for the Global Burden of Disease Study, 2010. Int J Methods Psychiatr Res. 2014;23:422-438.
8. Baxter AJ, Scott KM, Vos T, Whiteford HA. Global prevalence of anxiety disorders: a systematic review and meta-regression. Psychol Med. 2013;43(5):897-910.
9. World Health Organization. Depression and other common mental disorders: global health estimates;2017. Dostępna z: http://www. who.int/mental_health/management/depression/prevalence_ global_health_estimates/en/
10. Wittchen HU1, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 2011;21:655-679.
11. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators, and others. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study. The Lancet.2015;388: 1005.
12. Barrera TL, Norton PJ. Quality of life impairment in generalized anxiety disorder, social phobia, and panic disorder. J Anxiety Disord. 2009; 23:1086-1090.
13. Greenberg PE1, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR, et al. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry. 1999; 60(7): 427-435.
14. Wittchen HU, Kessler RC, Beesdo K, Krause P, Höfler M, Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry. 2002; 63 Suppl.8:24-34
15. Remes O, Brayne C, Van Der Linde R, Lafortune L. A systematic review of reviews on the prevalence of anxiety disorders in adult populations. Brain and Behavior. 2016;6:e00497.
16. Simpson HB, Neria Y, Lewis-Fernandez R, Schneier F. Anxiety disorders – theory, research and clinical perspectives. 1st ed. Cambridge University Press, Cambridge.2010.
17. Bandelow B, ReittM,Röver C, Michaelis S, Görlich Y, WedekindD. Efficacy of treatments for anxiety disorders: a meta-analysis. International Clinical Psychopharmacology. 2015;30:183-192.
18. Huang BT, Huang FY, Zuo Z, Liao YB, Heng Y, Wang PJ, et al. Meta-analysis of relation between oral β-blocker therapy and outcomes in patients with acute myocardial infarction who underwent percutaneous coronary intervention. The American journal of cardiology. 2015;115:1529-1538.
19. Task Force Members.2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). European heart journal. 2006;35:2383-2431.
20. Moran NC, Perkins ME. Adrenergic blockade of the mammalian heart by a dichloroanalogue of isoproterenol. Journal of pharmacology and experimental therapeutics.1958;124: 223-237.
21. William H., Frishman WH. Fifty years of beta-blockers: a revolution in CV pharmacotherapy. Cardiology Today. December 2008.
22. Black JW, Crowther AF, Shanks RG, Smith LH, Dornhost AC. A new adrenergic: beta-receptor antagonist. The Lancet. 1964;283:1080- 1081.
23. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in cardiovascular diseases1985; 27:335-371.
24. Julian DG, Jackson FS, Prescott RJ, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. The Lancet. 1982; 319: 1142-1147.
25. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Málek I, Nyberg G, et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. The Lancet. 1981;318: 823-827.
26. Frishman WH, Ruggio J, FurbergC. Use of beta-adrenergic blocking agents after myocardial infarction. Postgraduate medicine. 1985;78:40-53.
27. Veterans Administration Co-operative Study Group. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. I. Results of short-term titration with emphasis on racial differences in response. JAMA. 1982;248:1996-2003.
28. Domanski MJ, Krause-Steinrauf H, Massie BM, Deedwania P, Follmann D, Kovar Det al. A comparative analysis of the results from 4 trials of β-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. Journal of cardiac failure. 2003;9:354-363
29. Dooley TP. Treating anxiety with either beta blockers or antiemetic antimuscarinic drugs: a review. Mental Health in Family Medicine. 2015;11:89-99.
30. Kuch M, Syska-Sumińska J. Leki beta-adrenolityczne – zastosowanie kliniczne. W:Braksator W i in. Kardiologia praktyczna: dla lekarzy rodzinnych i studentów medycyny. T. 2, Farmakologia kliniczna. Warszawa: Akademia Medyczna, 2002. s. 43.
31. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;26: 1730-37.
32. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in- Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-7.
33. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
34. Di Lenarda A, Sabbadini G, Salvatore L, Sinagra G, Mestroni L, Pinamonti B et al. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol. 1999; 33:1926-34.
35. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection Rusing beta-blockers: a critical review of the evidence. J Am Coll Cardiol. 2007;50:563-72.
36. Turner P, Granville-Grossman KL Effect of adrenergic receptor blockade of the tachycardia of thyrotoxicosis and anxiety state. Lancet. 1965;2:1316-1318
37. Becker AL. Oxprenolol and propranolol in anxiety states. A double-blind comparative study. S Afr Med J.1976;50: 627-629.
38. Meibach RC, Dunner D, Wilson LG, Ishiki D, Dager SR. Comparativeefficacy of propranolol, chlordiazepoxide, and placebo in the treatment ofanxiety: A double-blind trial. J Clin Psychiatry. 1987;48:355-358.
39. Wheatley D. Comparative effects of propranolol and chlordiazepoxide in anxiety states. Br J Psychiatry 1969;115:1411-1412.
40. Brewer C. Beneficial effect of beta-adrenergic blockade on ‘exam nerves’. Lancet 1972;2:435.
41. Drew PJ, Barnes JN, Evans SJ. The effect of acute beta-adrenoceptorblockade on examination performance. Br J Clin Pharmacol 1985;19:783-786.
42. Clark DB, AgrasWS.The assessment and treatment of performanceanxiety in musicians. Am J Psychiatry 1991;148:598-605.
43. Brantigan CO, Brantigan TA, Joseph N. Effect of beta blockadeand beta stimulation on stage fright. Am J Med.1982;72: 88-94.
44. Elman MJ, Sugar J, Fiscella R, Deutsch TA, Noth J, Nyberg Met al. The effect of propranolol versusplacebo on resident surgical performance. Trans Am Ophthalmol Soc96: 283-291; discussion 1998;291-294.
45. Dyck JB, Chung F.A comparison of propranolol and diazepamfor preoperative anxiolysis. Can J Anaesth. 1991;38:704-709.
46. MacKinnon DF, Craighead B, Hoehn-Saric R. Carbon dioxide provocation of anxiety and respiratory response in bipolar disorder. Journal of affective disorders 2007;99: 45-49.
47. Papp LA, Martinez JM, Klein DF, Coplan JD, Norman RG, Cole Ret al. Respiratory psychophysiology of panic disorder: three respiratory challenges in 98 subjects. Am J Psychiatry. 1997;154.11: 1557- 1565.
48. Strohle A, Kellner M, Yassouridis A. Effect of flumazenil in lactate-sensitive patients with panic disorder. Am J Psychiatry.1998;155: 610-612.
49. Kronenberg G, Schredl M, Fiedler K. In healthy volunteers responses to challenge with cholecystokinin tetrapeptide differ between administration during REM and delta sleep. Depress Anxiety 2001;14:141-144.
50. Papadopoulos A, Rich A, Nutt DJ. The effects of single dose anxiolytic medication on the CO2 models of anxiety: differentiation of subjective and objective measures. Journal of psychopharmacology 2010; 24: 649-656.
51. Ravaris CL, Friedman MJ, Hauri PJ. A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients. J Psychopharmacol. 1991;11:344-350.
52. Steenen SA., van Wijk AJ, Van Der Heijden GJ, van Westrhenen R, de Lange J, de Jongh A. Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. J Psychopharmacol. 2016;30:128-139.
53. Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol., 2014;28:403-439.
54. Johansen JP, Cain CK, Ostroff LE, LeDoux JE. Molecular mechanisms of fear learning and memory. Cell 2011;147:509-524.
55. Kindt M, Soeter M and Vervliet B. Beyond extinction: Erasing human fear responses and preventing the return of fear. Nat Neurosci. 2009;12:256-258.
56. Soeter M and Kindt M. Dissociating response systems: Erasing fear from memory. Neurobiol Learn Mem. 2010;94:30-41
57. McGaugh JL. Memory – a century of consolidation. Science. 2000;287:248-251.
58. Cahill L, Prins B, Weber M, McGaugh JL. β-adrenergic activation and memory for emotional events. Nature 1994;371:702-704.
59. Van Stegeren AH, Everaerd W, Cahill L, McGaugh JL, Gooren LJ. Memory for emotional events: differential effects of centrally versus peripherally acting β -blocking agents. Nature 1998;138:305-310.
60. Van Stegeren AH, Goekoop R, Everaerd W. Scheltens P, Barkhof F, Kuijer JP et al. Norepinephrine mediates amygdala activation in men and women during encoding of emotional material. Neuroimage 2005;24:898-909.
61. Strange BA, Dolan RJ. Β-adrenergic modulation of emotional memory-evoked human amygdala and hippocampal responses. Proc. NatlAcad. Sci. USA 2004;101:11454-11458.
62. Hurlemann R, Walter H, Rehme AK, Kukolja J, Santoro SC, Schmidt C et al. Human amygdala reactivity is diminished by the β-noradrenergic antagonist propranolol. Psychological medicine. 2010;40:1839-1848.
63. Rimmele U, Lackovic SF, Tobe RH, Leventhal BL Phelps EA. Beta-adrenergic blockade at memory encoding, but not retrieval, decreases the subjective sense of recollection. Journal of cognitive neuroscience, 2016;28:895-907.
64. Schwabe L, Nader K, Wolf OT, Beaudry T, Pruessner JC. Neural signature of reconsolidation impairments by propranolol in humans. Biol Psychiatry. 2012;71:380-386.
65. Mahabir M, Ashbaugh AR , Saumier D , Tremblay J. Propranolol's impact on cognitive performance in post-traumatic stress disorder. J Affect Disord. 2016;192:98-103.
66. Hoge EA, Worthington JJ, Nagurney JT. Effect of acute posttrauma propranolol on PTSD outcome and physiological responses during script-driven imagery. CNS Neurosci Ther.2012;18:21-27.
67. Bell J. Propranolol, post-traumatic stress disorder and narrative identity. J Med Ethics.2008;34:e23.
68. Falloon IR, Lloyd GG, Harpin RE. The treatment of social phobia. Real-life rehearsal with nonprofessional therapists. J Nerv Mental Dis. 1981;169:180-184.
69. Neftel KA, Adler RH, Kappeli L. Stage fright in musicians: a model illustrating the effect of beta blockers. Psychosom Med. 1982; 44:461-469.
70. James I, Savage I. Beneficial effect of nadolol on anxietyinduced disturbances of performance in musicians: a comparison with diazepam and placebo. Am Heart J.1984;108:1150-1155.
71. Gates GA, Saegert J, Wilson N. Effect of beta blockade on singing performance. Ann OtolRhinolLaryngol.1985;94: 570-574.
72. James IM, Burgoyne W, Savage IT. Effect of pindolol on stress-related disturbances of musical performance: preliminary communication. J RSocMed.1983;76:194-196.
73. Swartz CM. Betaxolol in anxiety disorders. Ann Clin Psychiatry.1998;10:9-14.
74. Hallas CN, Wray J, Andreou P, Banner NR. Depression and perceptions about heart failure predict quality of life in patients with advanced heart failure. Heart Lung, 2011; 40:111-121.
75. Pajak A, Jankowski P, Kotseva K, Heidrich J, De Smedt D, De Bacquer D. Depression, anxiety, and risk factor control in patients after hospitalization for coronary heart disease: the EUROASPIRE III Study. Eur J PrevCardiol.2013;20:331-340.
76. Aburuz, ME. Anxiety and depression predicted quality of life among patients with heart failure. Journal of multidisciplinary healthcare, 2018, 11: 367.
77. Celano CM, Millstein RA, Bedoya CA, Healy BC, Roest AM, Huffman JC. Association between anxiety and mortality in patients with coronary artery disease: a meta-analysis. Am Heart J. 2015;170:1105-15.
78. Małyszczak, K; Rymaszewska, J. Depression and anxiety in cardiovascular disease. Kardiologia Polska (Polish Heart Journal), 2016, 74.7: 603-609.
79. Emdin, CA., et al. Meta-analysis of anxiety as a risk factor for cardiovascular disease. The American journal of cardiology, 2016, 118.4: 511-519
80. Moser DK. “The rust of life”: impact of anxiety on cardiac patients. Am J CritCare, 2007;16:361-369.
81. Moser DK., McKinley S, Riegel B, Doering LV, Meischke H, Pelter M, Dracup K. Relationship of persistent symptoms of anxiety to morbidity and mortality outcomes in patients with coronary heart disease. Psychosom Med. 2011;73: 803-809.
82. Yekehtaz, H; Farokhnia, M; Akhondzadeh, S. Cardiovascular considerations in antidepressant therapy: an evidence-based review. The Journal of Tehran University Heart Center, 2013, 8.4: 169.
83. Dharmarajan TS, Dharmarajan L. Tolerability of Antihypertensive Medications in Older Adults. Drugs Aging.2015;32:773-796.
84. Kubesova HM, Weber P, Meluzinova H, Bielakova K, Matejovsky J. Benefits and pitfalls of cardiovascular medication in seniors. Wiener klinischeWochenschrift. 2013;125:425-436.
85. Crocco EA, Jaramillo S, Cruz-Ortiz C, Camfield K. Pharmacological Management of Anxiety Disorders in the Elderly. CurrTreatOptions Psychiatry. 2017;4:33-46.
86. Molden E, SpigsetaO. Interactions between metoprolol and antidepressants. Tidsskr Nor Laegeforen. 2011;131:1777-9
87. Boal AH, Smith DJ, McCallum L, Muir S, Touyz RM, Dominiczak AF et al. Monotherapy With Major Antihypertensive Drug Classes and Risk of Hospital Admissions for Mood Disorders. Hypertension. 2016;68:1132-1138.
88. Liu X, Lou X, Cheng X, Meng Y. Impact of metoprolol treatment on mental status of chronic heart failure patients with neuropsychiatric disorders. Drug Des DevelTher. 201711:305-312.
89. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM: B-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002; 288:351-357
90. Joost P van Melle JP, Verbeek DEP, van den Berg MP, Ormel J, van der Linde MR, de Jonge. Beta-blockers and depression after myocardial infarction. J Am Coll Cardiol. 2006;48:2209-2214.
91. Ranchord AM, Spertus JA, Buchanan DM, Gosch KL, Chan PS.Initiation of β-blocker therapy and depression after acute myocardial infarction. Am Heart J. 2016;174:37-42.
92. Kent LK, Weston CA, Heyer EJ, Sherman W, Prudic J. Successful retrial of ECT two months after ECT-induced takotsubo cardiomyopathy. Am J Psychiatry. 2009; 166:857-862.
93. Crane PB, Oles KS, Kennedy-Malone L. Beta-blocker medication usage in older women after myocardial infarction. J Am Acad Nurse Pract 2006;18:463-470.
94. Tucker WD, Whitten RA. Selektywne Beta -1 blokery. Stat Pearls [Internet]. Treasure Island (FL):StatPearls Publishing 2018.
95. Roy-Byrne P, Stein M, Hermann R. Farmakoterapia na zespół lęku napadowego. W: Post T, redaktor naczelny. (red.) Up To Date. Waltham, MA: Up To Date dostępne na stronie: http://www.uptodate.com/contents/pharmacotherapyforpanicdisorder (dostęp 9 lipca 2015 r.).
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2018 Authors